Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Active, not recruiting Phase 3 Interventional

Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-3)

ClinicalTrials.gov ID: NCT06358651

Public ClinicalTrials.gov record NCT06358651. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 1:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

US, Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial of Fasedienol Nasal Spray for the Acute Treatment of Anxiety Induced by a Public Speaking Challenge in Adult Subjects With Social Anxiety Disorder, With an Open-Label Extension (PALISADE-3)

Study identification

NCT ID
NCT06358651
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
VistaGen Therapeutics, Inc.
Industry
Enrollment
238 participants

Conditions and interventions

Interventions

  • Fasedienol Nasal Spray Drug
  • Placebo Nasal Spray Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 65 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 27, 2024
Primary completion
Oct 30, 2025
Completion
Sep 30, 2026
Last update posted
Nov 25, 2025

2024 – 2026

United States locations

U.S. sites
24
U.S. states
18
U.S. cities
24
Facility City State ZIP Site status
Vistagen Clinical Site Phoenix Arizona 85012
Vistagen Clinical Site Fayetteville Arkansas 72703
Vistagen Clinical Site Little Rock Arkansas 72211
Vistagen Clinical Site Lafayette California 94549
Vistagen Clinical Site Oceanside California 92056
Vistagen Clinical Site Sherman Oaks California 91403
Vistagen Clinical Site Denver Colorado 80209
Vistagen Clinical Site Cromwell Connecticut 06416
Vistagen Clinical Site Jacksonville Florida 32256
Vistagen Clinical Site Lakeland Florida 33803
Vistagen Clinical Site Orlando Florida 32801
Vistagen Clinical Site West Palm Beach Florida 33407
Vistagen Clinical Site Chicago Illinois 60612
Vistagen Clinical Site Overland Park Kansas 66210
Vistagen Clinical Site Baltimore Maryland 21208
Vistagen Clinical Site Boston Massachusetts 02131
Vistagen Clinical Site Saint Charles Missouri 63304
Vistagen Clinical Site Las Vegas Nevada 89119
Vistagen Clinical Site New York New York 10128
Vistagen Clinical Site Media Pennsylvania 19063
Vistagen Clinical Site Memphis Tennessee 38119
Vistagen Clinical Site Fort Worth Texas 76104
Vistagen Clinical Site Draper Utah 84020
Vistagen Clinical Site Everett Washington 98201

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06358651, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 25, 2025 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06358651 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →